HC Wainwright restated their buy rating on shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in a research note released on Tuesday, Marketbeat Ratings reports. HC Wainwright currently has a $33.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $18.00.
Several other analysts have also recently weighed in on TGTX. Zacks Investment Research cut TG Therapeutics from a hold rating to a sell rating in a report on Saturday, August 12th. BidaskClub cut TG Therapeutics from a hold rating to a sell rating in a report on Saturday, August 5th. SunTrust Banks, Inc. reissued a buy rating and set a $28.00 price target on shares of TG Therapeutics in a report on Tuesday, October 3rd. Finally, ValuEngine cut TG Therapeutics from a hold rating to a sell rating in a report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. TG Therapeutics currently has a consensus rating of Buy and an average price target of $26.78.
Shares of TG Therapeutics (TGTX) opened at $7.70 on Tuesday. TG Therapeutics has a fifty-two week low of $4.10 and a fifty-two week high of $15.35.
ILLEGAL ACTIVITY WARNING: This story was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/18/hc-wainwright-reaffirms-buy-rating-for-tg-therapeutics-inc-tgtx.html.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc raised its holdings in TG Therapeutics by 4.1% in the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 384 shares in the last quarter. Bank of America Corp DE raised its holdings in TG Therapeutics by 11.0% in the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after acquiring an additional 1,395 shares in the last quarter. UBS Group AG raised its holdings in TG Therapeutics by 34.4% in the 1st quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock valued at $171,000 after acquiring an additional 3,736 shares in the last quarter. HighTower Advisors LLC acquired a new position in TG Therapeutics in the 1st quarter valued at $170,000. Finally, Fox Run Management L.L.C. acquired a new position in TG Therapeutics in the 2nd quarter valued at $156,000. 49.58% of the stock is owned by hedge funds and other institutional investors.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
What are top analysts saying about TG Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TG Therapeutics Inc. and related companies.